These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30294708)

  • 1. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study.
    Willian MK; D'Haens G; Yarlas A; Joshi AV
    J Patient Rep Outcomes; 2018 Dec; 2():22. PubMed ID: 30294708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.
    Yarlas A; D'Haens G; Willian MK; Teynor M
    Inflamm Bowel Dis; 2018 Jan; 24(2):450-463. PubMed ID: 29361097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis.
    Hodgkins P; Yen L; Yarlas A; Karlstadt R; Solomon D; Kane S
    Inflamm Bowel Dis; 2013 Feb; 19(2):386-96. PubMed ID: 22648999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.
    Yarlas A; Willian MK; Nag A
    Qual Life Res; 2021 Jul; 30(7):1925-1938. PubMed ID: 33651279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study.
    Croft NM; Korczowski B; Kierkuś J; Caballero B; Thakur MK
    EClinicalMedicine; 2023 Nov; 65():102232. PubMed ID: 37855022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.
    Yarlas A; Yen L; Hodgkins P
    Qual Life Res; 2015 Mar; 24(3):671-83. PubMed ID: 25193617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
    Rubin DT; Cohen RD; Sandborn WJ; Lichtenstein GR; Axler J; Riddell RH; Zhu C; Barrett AC; Bortey E; Forbes WP
    J Crohns Colitis; 2017 Jul; 11(7):785-791. PubMed ID: 28333362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.
    Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S
    BMC Gastroenterol; 2021 Apr; 21(1):161. PubMed ID: 33845784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
    Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
    Schreiber S; Hanauer SB; Sandborn WJ; Barrett K
    J Crohns Colitis; 2020 Sep; 14(9):1274-1281. PubMed ID: 32179906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.
    Panés J; Loftus EV; Higgins PDR; Lindsay JO; Zhou W; Yao X; Ilo D; Phillips C; Tran J; Sanchez Gonzalez Y; Vermeire S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1421-1430. PubMed ID: 36645051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results.
    Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S
    World J Gastroenterol; 2020 Jun; 26(21):2852-2863. PubMed ID: 32550760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
    Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D'Haens G;
    J Crohns Colitis; 2016 Aug; 10(8):925-33. PubMed ID: 26908939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis.
    Kane S; Katz S; Jamal MM; Safdi M; Dolin B; Solomon D; Palmen M; Barrett K
    Inflamm Bowel Dis; 2012 Jun; 18(6):1026-33. PubMed ID: 21837775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.
    Osterman MT; Aberra FN; Cross R; Liakos S; McCabe R; Shafran I; Wolf D; Hardi R; Nessel L; Brensinger C; Gilroy E; Lewis JD;
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1887-93.e3. PubMed ID: 24793028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
    Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
    Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
    Cuffari C; Pierce D; Korczowski B; Fyderek K; Van Heusen H; Hossack S; Wan H; Edwards AY; Martin P
    Drug Des Devel Ther; 2016; 10():593-607. PubMed ID: 26893546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial.
    Schreiber S; Feagan BG; Peyrin-Biroulet L; Vermeire S; Faes M; Harris K; Oortwijn A; Daniele P; Patel H; Danese S
    J Crohns Colitis; 2023 Jun; 17(6):863-875. PubMed ID: 36756874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
    Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?
    Bellone F; Morace C; Impalà G; Viola A; Lo Gullo A; Cinquegrani M; Fries W; Sardella A; Scolaro M; Basile G; Squadrito G; Mandraffino G
    J Pers Med; 2023 Jun; 13(6):. PubMed ID: 37373936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.